Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CELU | US
-0.18
-6.47%
Healthcare
Biotechnology
30/06/2024
17/10/2024
2.60
2.94
2.94
2.60
Celularity Inc. a clinical-stage biotechnology company develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer immune and infectious diseases. It operates through three segments: Cell Therapy Degenerative Disease and BioBanking. The company's lead therapeutic programs include CYCART-19 an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001 an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001 a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL and human epidermal growth factor receptor 2 positive cancers; CYNK-301 a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302 a CAR-NK to treat non-small cell lung cancer; and pExo-001 a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces sells and licenses products that are used in surgical and wound care markets such as Biovance Biovance 3L Interfyl and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics Inc. for the development and commercialization of licensed CD19 CAR-T products. The company was founded in 1998 and is based in Florham Park New Jersey.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
81.8%1 month
79.5%3 months
66.6%6 months
81.2%-
-
1.35
1.60
0.45
-36.78
5.29
-
-67.16M
57.16M
57.16M
-
-89.55
-61.30
193.30
-163.67
46.20
10.37
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.57
Range1M
0.63
Range3M
1.00
Rel. volume
0.56
Price X volume
27.82K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 2.09 | 62.68M | -5.86% | n/a | 6.50% |
iShares MSCI Brazil ETF USD Acc | CSBR | Biotechnology | 4.44 | 60.36M | -2.63% | n/a | -2140.66% |
Kezar Life Sciences Inc | KZR | Biotechnology | 0.816 | 59.54M | -8.80% | n/a | 11.69% |
Omega Therapeutics Inc. Common Stock | OMGA | Biotechnology | 1.04 | 59.05M | 14.96% | n/a | 483.39% |
RAPT THERAPEUTICS INC. | RAPT | Biotechnology | 1.69 | 58.99M | -3.43% | n/a | 5.24% |
CEL-SCI Corporation | CVM | Biotechnology | 0.95 | 58.42M | -3.57% | n/a | 143.19% |
Allakos Inc | ALLK | Biotechnology | 0.65 | 57.75M | -1.28% | n/a | 47.30% |
Kronos Bio Inc | KRON | Biotechnology | 0.93 | 56.07M | -3.63% | n/a | 22.03% |
Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.72 | 53.59M | 2.38% | n/a | 4.22% |
OncoCyte Corporation | OCX | Biotechnology | 3.12 | 53.39M | 0.32% | n/a | 16.15% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -36.78 | 0.53 | Cheaper |
Ent. to Revenue | 5.29 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.35 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 66.56 | 72.92 | Par |
Debt to Equity | 1.60 | -1.24 | Expensive |
Debt to Assets | 0.45 | 0.25 | Expensive |
Market Cap | 57.16M | 3.78B | Emerging |